Drug intelligence / Profile preview

TG4040

Development stage: Phase 2
Lead developer: Transgene
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

TG4040 is an investigational therapeutic vaccine developed for the treatment of chronic hepatitis C virus (HCV) infection. It is based on a modified vaccinia Ankara (MVA) viral vector that expresses non-structural proteins of HCV, specifically NS3, NS4, and NS5B. The primary mechanism of action is to induce a strong and broad T cell-mediated immune response against HCV-infected cells by stimulating the immune system to recognize and attack these viral proteins. TG4040 was developed by Transgene and has undergone phase I and II clinical trials in combination with standard-of-care therapies such as pegylated interferon alpha-2a and ribavirin in patients with chronic HCV genotype 1 infection. Despite promising immunogenicity data, development for hepatitis C was discontinued after phase II trials[1][2][3][4][5].

Other names: HCV therapeutic vaccine - TransgeneHepatitis C vaccine - Transgene

Targets

Hepatitis C virus NS3/NS4/NS5B antigens

Beyond the preview

Go deeper on TG4040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG4040.

Explore the full profile